---
title: "Compass Pathways to attend TD Cowen 46th Annual Healthcare Conference in Boston, MA from March 2-4, 2026 | CMPS Stock News"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/276726781.md"
description: "Compass Pathways plc (Nasdaq: CMPS) will attend the TD Cowen 46th Annual Healthcare Conference in Boston, MA, from March 2-4, 2026. Management will participate in a fireside chat on March 3, 2026, at 10:30 am ET. A live audio webcast will be available on the company's website, with a replay accessible for 30 days. Compass Pathways focuses on innovative mental health treatments, including its investigational COMP360 synthetic psilocybin treatment, which has received Breakthrough Therapy designation from the FDA for treatment-resistant depression."
datetime: "2026-02-24T03:39:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/276726781.md)
  - [en](https://longbridge.com/en/news/276726781.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/276726781.md)
---

# Compass Pathways to attend TD Cowen 46th Annual Healthcare Conference in Boston, MA from March 2-4, 2026 | CMPS Stock News

LONDON & NEW YORK--(BUSINESS WIRE)--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will attend the TD Cowen 46th Annual Healthcare Conference in Boston, MA, from March 2-4, 2026 and will participate in a fireside chat on March 3, 2026 at 10:30am ET.

A live audio webcast of this event will be accessible from the “Events” page of the Investors section of the Compass website. A replay of the webcast will be accessible for 30 days following each event.

**About Compass Pathways**

Compass Pathways plc (Nasdaq: CMPS) is a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. We are motivated by the need to find better ways to help and empower people with serious mental health conditions who are not helped by existing treatments. We are pioneering a new paradigm for treating mental health conditions focused on rapid and durable responses through the development of our investigational COMP360 synthetic psilocybin treatment, potentially a first in class treatment. COMP360 has Breakthrough Therapy designation from the US Food and Drug Administration (FDA) and has received Innovative Licensing and Access Pathway (ILAP) designation in the UK for treatment-resistant depression (TRD).

Compass is headquartered in London, UK, with offices in New York in the US. We envision a world where mental health means not just the absence of illness but the ability to thrive.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260224020625/en/

**Enquiries**  
Media: Dana Sultan-Rothman, media@compasspathways.com

Investors: Stephen Schultz, stephen.schultz@compasspathways.com, +1 401 290 7324

Source: Compass Pathfinder Limited

### Related Stocks

- [CMPS.US](https://longbridge.com/en/quote/CMPS.US.md)

## Related News & Research

- [Compass Pathways Touts Phase 3 COMP360 Depression Data, Eyes Rolling NDA and 2026 Launch Readiness](https://longbridge.com/en/news/282817667.md)
- [Annual General Meeting 2026 Resolutions | SBFFF Stock News](https://longbridge.com/en/news/282875133.md)
- [.B. Q1 2026 Earnings Preview](https://longbridge.com/en/news/282902757.md)
- [Kosmos Energy to Host First Quarter 2026 Results and Webcast on May 5, 2026 | KOS Stock News](https://longbridge.com/en/news/282790965.md)
- [trivago N.V.'s First Quarter 2026 Earnings Release Scheduled for May 5, 2026; Webcast Scheduled for May 6, 2026 | TRVG Stock News](https://longbridge.com/en/news/282808060.md)